Valicenti Advisory Services Inc. decreased its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 1.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 57,997 shares of the financial services provider’s stock after selling 575 shares during the quarter. iShares Biotechnology ETF comprises approximately 2.3% of Valicenti Advisory Services Inc.’s investment portfolio, making the stock its 14th largest holding. Valicenti Advisory Services Inc. owned about 0.10% of iShares Biotechnology ETF worth $7,363,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Vontobel Holding Ltd. grew its position in iShares Biotechnology ETF by 9.5% in the 1st quarter. Vontobel Holding Ltd. now owns 5,060 shares of the financial services provider’s stock valued at $659,000 after purchasing an additional 440 shares during the period. Blair William & Co. IL grew its position in iShares Biotechnology ETF by 9.7% in the 1st quarter. Blair William & Co. IL now owns 18,717 shares of the financial services provider’s stock valued at $2,439,000 after purchasing an additional 1,659 shares during the period. NewEdge Advisors LLC grew its position in iShares Biotechnology ETF by 11.7% in the 1st quarter. NewEdge Advisors LLC now owns 13,777 shares of the financial services provider’s stock valued at $1,796,000 after purchasing an additional 1,445 shares during the period. DCF Advisers LLC acquired a new stake in iShares Biotechnology ETF in the 1st quarter valued at $912,000. Finally, Laurel Wealth Advisors Inc. grew its position in iShares Biotechnology ETF by 22.6% in the 1st quarter. Laurel Wealth Advisors Inc. now owns 3,019 shares of the financial services provider’s stock valued at $393,000 after purchasing an additional 557 shares during the period. Institutional investors and hedge funds own 69.61% of the company’s stock.
iShares Biotechnology ETF Stock Performance
NASDAQ IBB traded up $0.48 during mid-day trading on Tuesday, hitting $125.73. The company’s stock had a trading volume of 110,970 shares, compared to its average volume of 1,510,731. The company’s 50 day simple moving average is $128.05 and its 200 day simple moving average is $129.30. iShares Biotechnology ETF has a twelve month low of $113.37 and a twelve month high of $138.74.
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
- Five stocks we like better than iShares Biotechnology ETF
- How Investors Can Identify and Successfully Trade Gap-Up Stocks
- 2 Beauty Stocks Beaten By the Ugly Stick But Ready to Rally
- 5 Top Rated Dividend Stocks to Consider
- Got Nuclear? Three Stocks To Play Energy’s Next Frontier
- How to Buy Cheap Stocks Step by Step
- The Top 4 Utilities for Value, Yield, and Upside Potential
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.